S&P 500   3,835.62 (+1.78%)
DOW   31,438.49 (+1.66%)
QQQ   307.50 (+1.12%)
AAPL   120.72 (+0.49%)
MSFT   232.01 (+2.33%)
FB   262.28 (+1.80%)
GOOGL   2,081.31 (+2.33%)
TSLA   597.00 (-3.93%)
AMZN   2,975.08 (-0.08%)
NVDA   496.71 (+0.38%)
BABA   233.33 (+1.23%)
CGC   30.75 (-0.84%)
GE   13.51 (-0.44%)
MU   88.43 (+4.86%)
NIO   36.75 (-6.44%)
AMD   78.13 (+0.49%)
T   29.67 (+2.59%)
F   12.15 (+1.84%)
ACB   9.47 (-3.56%)
DIS   188.86 (+0.44%)
BA   219.95 (-2.12%)
NFLX   510.72 (-0.11%)
BAC   36.80 (+0.82%)
S&P 500   3,835.62 (+1.78%)
DOW   31,438.49 (+1.66%)
QQQ   307.50 (+1.12%)
AAPL   120.72 (+0.49%)
MSFT   232.01 (+2.33%)
FB   262.28 (+1.80%)
GOOGL   2,081.31 (+2.33%)
TSLA   597.00 (-3.93%)
AMZN   2,975.08 (-0.08%)
NVDA   496.71 (+0.38%)
BABA   233.33 (+1.23%)
CGC   30.75 (-0.84%)
GE   13.51 (-0.44%)
MU   88.43 (+4.86%)
NIO   36.75 (-6.44%)
AMD   78.13 (+0.49%)
T   29.67 (+2.59%)
F   12.15 (+1.84%)
ACB   9.47 (-3.56%)
DIS   188.86 (+0.44%)
BA   219.95 (-2.12%)
NFLX   510.72 (-0.11%)
BAC   36.80 (+0.82%)
S&P 500   3,835.62 (+1.78%)
DOW   31,438.49 (+1.66%)
QQQ   307.50 (+1.12%)
AAPL   120.72 (+0.49%)
MSFT   232.01 (+2.33%)
FB   262.28 (+1.80%)
GOOGL   2,081.31 (+2.33%)
TSLA   597.00 (-3.93%)
AMZN   2,975.08 (-0.08%)
NVDA   496.71 (+0.38%)
BABA   233.33 (+1.23%)
CGC   30.75 (-0.84%)
GE   13.51 (-0.44%)
MU   88.43 (+4.86%)
NIO   36.75 (-6.44%)
AMD   78.13 (+0.49%)
T   29.67 (+2.59%)
F   12.15 (+1.84%)
ACB   9.47 (-3.56%)
DIS   188.86 (+0.44%)
BA   219.95 (-2.12%)
NFLX   510.72 (-0.11%)
BAC   36.80 (+0.82%)
S&P 500   3,835.62 (+1.78%)
DOW   31,438.49 (+1.66%)
QQQ   307.50 (+1.12%)
AAPL   120.72 (+0.49%)
MSFT   232.01 (+2.33%)
FB   262.28 (+1.80%)
GOOGL   2,081.31 (+2.33%)
TSLA   597.00 (-3.93%)
AMZN   2,975.08 (-0.08%)
NVDA   496.71 (+0.38%)
BABA   233.33 (+1.23%)
CGC   30.75 (-0.84%)
GE   13.51 (-0.44%)
MU   88.43 (+4.86%)
NIO   36.75 (-6.44%)
AMD   78.13 (+0.49%)
T   29.67 (+2.59%)
F   12.15 (+1.84%)
ACB   9.47 (-3.56%)
DIS   188.86 (+0.44%)
BA   219.95 (-2.12%)
NFLX   510.72 (-0.11%)
BAC   36.80 (+0.82%)
Log in
NASDAQ:CRVS

Corvus Pharmaceuticals Stock Forecast, Price & News

$2.85
-0.06 (-2.06 %)
(As of 03/5/2021 02:40 PM ET)
Add
Compare
Today's Range
$2.61
Now: $2.85▼
$2.95
50-Day Range
$3.17
MA: $3.85▼
$4.77
52-Week Range
$1.01
Now: $2.85▼
$6.88
Volume50,266 shs
Average Volume1.12 million shs
Market Capitalization$79.98 million
P/E RatioN/A
Dividend YieldN/A
Beta1.81
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/2 clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and stimulate various immune cells, as well as Phase I clinical trial of CPI-006 for COVID-19; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2-inducible T-cell kinase, that is Phase I/Ib clinical trial. Corvus Pharmaceuticals, Inc. also entered into a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was founded in 2014 and is based in Burlingame, California.
Corvus Pharmaceuticals logo

Headlines

Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences
March 5, 2021 |  finance.yahoo.com
Co-Founder Richard Miller Just Bought 8.5% More Shares In Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)
February 19, 2021 |  finance.yahoo.com
Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock
February 17, 2021 |  finance.yahoo.com
Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
February 12, 2021 |  finance.yahoo.com
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock
February 11, 2021 |  finance.yahoo.com
Top Analyst Upgrades and Downgrades: Akamai, Avaya, Canopy Growth, Corsair Gaming, Playtika, Virgin Galactic and More
February 10, 2021 |  msn.com
Corvus Initiates CPI-006 Pivotal Trial In COVID-19 Patients; Results Expected by 2021 End
February 4, 2021 |  finance.yahoo.com
Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19
February 4, 2021 |  finance.yahoo.com
What Type Of Shareholders Make Up Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Share Registry?
January 30, 2021 |  finance.yahoo.com
Is CRVS A Good Stock To Buy Now?
December 7, 2020 |  finance.yahoo.com
Corvus Presents New Data on its Investigational ITK Inhibitor CPI-818 at the American Society of Hematology (ASH) Annual Meeting & Exposition
December 6, 2020 |  finance.yahoo.com
Corvus Announces Upcoming CPI-818 Data Presentations at the American Society of Hematology (ASH) Annual Meeting & Exposition
November 30, 2020 |  finance.yahoo.com
Corvus Hosting R&D Symposium on November 12 to Highlight COVID-19 Program and Updated Study Data Presented at SITC Annual Meeting
November 11, 2020 |  finance.yahoo.com
Corvus' immunotherapy shows durable benefit in COVID-19
November 9, 2020 |  seekingalpha.com
Corvus Completes Enrollment in Phase 1 Study of CPI-006 for Patients with COVID-19 and Presents Study Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 9, 2020 |  finance.yahoo.com
Corvus Pharmaceuticals COVID-19 Abstract Selected for “Hot Topic” Oral Session at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2, 2020 |  finance.yahoo.com
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth Carefully
November 1, 2020 |  finance.yahoo.com
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results
October 29, 2020 |  finance.yahoo.com
Corvus Pharmaceuticals to Present Updated Data from its Clinical Trial of CPI-006 for Patients with COVID-19 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 29, 2020 |  finance.yahoo.com
Corvus Shares Surge After Positive Data From Early Stage Study On COVID-19 Treatment
October 7, 2020 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRVS
Previous Symbol
CUSIPN/A
CIK1626971
Webwww.corvuspharma.com
Phone650-900-4520
Employees52
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio4.38
Quick Ratio4.38

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.42 per share
Price / Book1.18

Profitability

EPS (Most Recent Fiscal Year)($1.59)
Net Income$-46,670,000.00
Net MarginsN/A
Return on Equity-79.15%
Return on Assets-63.99%

Miscellaneous

Outstanding Shares28,062,000
Market Cap$79.98 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank™

Overall MarketRank™

1.83 out of 5 stars

Medical Sector

139th out of 1,972 stocks

Pharmaceutical Preparations Industry

58th out of 772 stocks

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -
$2.85
-0.06 (-2.06 %)
(As of 03/5/2021 02:40 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRVS News and Ratings via Email

Sign-up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions

Is Corvus Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Corvus Pharmaceuticals stock.
View analyst ratings for Corvus Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Corvus Pharmaceuticals?

Wall Street analysts have given Corvus Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Corvus Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Corvus Pharmaceuticals' earnings last quarter?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) posted its earnings results on Thursday, October, 29th. The company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.24) by $0.09.
View Corvus Pharmaceuticals' earnings history.

How has Corvus Pharmaceuticals' stock price been impacted by COVID-19?

Corvus Pharmaceuticals' stock was trading at $2.71 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CRVS stock has increased by 8.9% and is now trading at $2.95.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for CRVS?

3 analysts have issued 12 month price targets for Corvus Pharmaceuticals' shares. Their forecasts range from $4.00 to $12.00. On average, they anticipate Corvus Pharmaceuticals' stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 171.2% from the stock's current price.
View analysts' price targets for Corvus Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Corvus Pharmaceuticals' key executives?

Corvus Pharmaceuticals' management team includes the following people:
  • Dr. Richard A. Miller, Co-Founder, Pres, CEO & Chairman (Age 70, Pay $303k)
  • Dr. Peter A. Thompson, Co-Founder & Independent Director (Age 61, Pay $47k)
  • Mr. Leiv Lea, Chief Financial Officer (Age 67, Pay $352.31k)
  • Dr. Mehrdad Mobasher M.D., M.P.H., VP & Chief Medical Officer (Age 48, Pay $654.73k)
  • Ms. Debra Horen SPHR, VP of HR
  • Dr. William Benton Jones, Sr. VP of Pharmaceutical Devel. (Age 55)
  • Mr. Alan C. Mendelson Esq., Sec.
  • Stephen Willingham, Sr. Scientist

What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO?

4 employees have rated Corvus Pharmaceuticals CEO Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among Corvus Pharmaceuticals' employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Corvus Pharmaceuticals' key competitors?

Some companies that are related to Corvus Pharmaceuticals include Trevena (TRVN), Immunome (IMNM), Paratek Pharmaceuticals (PRTK), Sesen Bio (SESN), CymaBay Therapeutics (CBAY), Oncorus (ONCR), NextCure (NXTC), Tonix Pharmaceuticals (TNXP), Immunic (IMUX), RedHill Biopharma (RDHL), VistaGen Therapeutics (VTGN), Alpine Immune Sciences (ALPN), iBio (IBIO), BELLUS Health (BLU) and Theratechnologies (THTX).
View all of CRVS's competitors.

What other stocks do shareholders of Corvus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO).

When did Corvus Pharmaceuticals IPO?

(CRVS) raised $75 million in an IPO on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

What is Corvus Pharmaceuticals' stock symbol?

Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."

Who are Corvus Pharmaceuticals' major shareholders?

Corvus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.84%), CHI Advisors LLC (1.75%), BlackRock Inc. (0.25%), Truist Financial Corp (0.07%) and Golden Green Inc. (0.07%). Company insiders that own Corvus Pharmaceuticals stock include Holdings A/S Novo, Leiv Lea, Orbimed Advisors Llc, Peter A Thompson and Richard A Md Miller.
View institutional ownership trends for Corvus Pharmaceuticals.

Which institutional investors are selling Corvus Pharmaceuticals stock?

CRVS stock was sold by a variety of institutional investors in the last quarter, including CHI Advisors LLC, BlackRock Inc., and Renaissance Technologies LLC.
View insider buying and selling activity for Corvus Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Corvus Pharmaceuticals stock?

CRVS stock was acquired by a variety of institutional investors in the last quarter, including Truist Financial Corp, and Golden Green Inc.. Company insiders that have bought Corvus Pharmaceuticals stock in the last two years include Leiv Lea, Orbimed Advisors Llc, Peter A Thompson, and Richard A Md Miller.
View insider buying and selling activity for Corvus Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Corvus Pharmaceuticals?

Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corvus Pharmaceuticals' stock price today?

One share of CRVS stock can currently be purchased for approximately $2.95.

How much money does Corvus Pharmaceuticals make?

Corvus Pharmaceuticals has a market capitalization of $82.78 million. The company earns $-46,670,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis.

How many employees does Corvus Pharmaceuticals have?

Corvus Pharmaceuticals employs 52 workers across the globe.

What is Corvus Pharmaceuticals' official website?

The official website for Corvus Pharmaceuticals is www.corvuspharma.com.

Where are Corvus Pharmaceuticals' headquarters?

Corvus Pharmaceuticals is headquartered at 863 Mitten Road Suite102, BURLINGAME CA, 94010.

How can I contact Corvus Pharmaceuticals?

Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at 650-900-4520 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.